朱秀华

瑞舒伐他汀联合曲美他嗪治疗冠心病合并高脂血症临床疗效分析

朱秀华

目的 分析探讨瑞舒伐他汀联合曲美他嗪治疗冠心病合并高脂血症的临床效果。方法 选取80例冠心病合并高脂血症患者随机分为治疗组40例对照组40例，两组患者均给予常规治疗，治疗组在常规治疗基础上给予瑞舒伐他汀联合曲美他嗪治疗，疗程为12周，对比分析两组患者治疗有效率及血脂水平的变化。结果 治疗组的总有效率高于对照组，差异具有统计学意义（P＜0.05），治疗组血脂水平改善程度均优于对照组，差异具有统计学意义（P＜0.05）。结论 瑞舒伐他汀联合曲美他嗪治疗冠心病合并高脂血症的临床疗效优良。

瑞舒伐他汀；曲美他嗪；冠心病合并高脂血症

doi：10.3969/j.issn.1674-9316.2016.13.068

【Abstract】

Objective To analyze clinical effect of rosuvastatin combined with trimetazidine in the treatment coronary heart disease complicated with hyperlipidemia. Methods Selected 80 case of patients with coronary heart disease complicated with hyperlipidemia were randomly divided into treatment group and control group，40 case in each group. The patients in two groups were given medical conventional treatment，treatment group received rosuvastatin combined with trimetazidine treatment，12 week as a cycle，compared treatment effect and the changes of blood lipid levels in the two groups. Results The total effective rate of the treatment group was significantly higher than that of the control group，the difference was statistically significant（P＜0.05）. The improvement of blood lipid in the treatment group was significantly better than that in the control group，the differencewas statistically significant（P＜0.05）. Conclusion Rosuvastatin combined with trimetazidine have a significant effect in the treatment of coronary heart disease complicated with hyperlipidemia.

1　资料与方法

1.1一般资料

研究对象共80例，均来自该院心内科2014年6月1日～2015 年12月31日收治的冠心病合并高脂血症患者，纳入标准：（1）有典型的心绞痛发作史、临床表现或有心肌缺血的心电图改变；（2）符合下述的1项或者多项即为高脂血症：患者空腹血浆总胆固醇（TC）大于5.20 mmol/L，或者低密度脂蛋白胆固醇（LDL-C）大于3.12 mmol/L，或者甘油三酯（TG）大于1.7 mmol/L。将急性心肌梗死、严重心、肝、肾功能不全、肿瘤及合并严重感染患者全部排除。所有入选患者均签署了知情同意书。将80例患者随机分为对照组和治疗组，其中对照组40例，男25例，女15例，年龄40～74岁，平均年龄（56.8±2.8）岁，治疗组40例，男27例，女13例，年龄41～74岁，平均年龄（57.8±2.5）岁。两组患者在性别、年龄、临床表现、血脂水平等方面比较，差异无统计学意义（P＞0.05）。……